Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Matthew McMurdo Resigns

Indaptus Therapeutics, Inc.

Tim Ruan, 40, CFO of Ocumension Therapeutics and former Executive Director at Goldman Sachs, appointed as Class II director.
Dr. Johnny Fox Arrowsmith (Yi Zhang), 48, partner at JunHe and registered patent attorney, appointed as Class II director.
Matthew McMurdo resigned as director on April 22, 2026; resignation not due to any disagreement with company.
Each new director receives annual cash retainer of $30,000, payable quarterly, plus expense reimbursement and indemnification.
Ruan appointed to Audit Committee; Arrowsmith appointed to Nominating Committee. New directors effective April 22, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.